A visfatin gene promoter polymorphism (rs1319501) is associated with susceptibility to nonalcoholic fatty liver disease

Per Med. 2023 Mar;20(2):157-165. doi: 10.2217/pme-2022-0100. Epub 2023 May 18.

Abstract

Background: Considering the role of visfatin in nonalcoholic fatty liver disease (NAFLD), a growing global epidemic, this article explores the potential association between the visfatin gene (NAMPT) and NAFLD. Methods: We used the PCR-restriction fragment length polymorphism method to genotype the rs1319501 promoter variant of the NAMPT gene in 154 patients with biopsy-proven NAFLD and 158 controls in this case-control genetic association study. Results: The 'CC+TC' genotype of NAMPT rs1319501 in comparison to the 'TT' genotype occurred less frequently in the cases with NAFLD than the controls, and the difference remained significant after adjustment for confounding factors (p = 0.029; odds ratio = 0.55; 95% CI = 0.31-0.82). Conclusion: This study showed, for the first time, that the carriers of the NAMPT rs1319501 'CC+TC' genotype had a 45% decreased risk for NAFLD.

Keywords: NAFLD; NAMPT; gene; insulin; polymorphism; visfatin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Genotype
  • Humans
  • Nicotinamide Phosphoribosyltransferase / genetics
  • Non-alcoholic Fatty Liver Disease* / genetics
  • Polymerase Chain Reaction
  • Polymorphism, Genetic

Substances

  • Nicotinamide Phosphoribosyltransferase
  • nicotinamide phosphoribosyltransferase, human